Our top pick for
NextGen Healthcare, Inc is a health information services business based in the US. NextGen Healthcare shares (NXGN) are listed on the NASDAQ and all prices are listed in US Dollars. NextGen Healthcare employs 2,754 staff and has a trailing 12-month revenue of around USD$549 million.
|52-week range||USD$5.1 - USD$23.8|
|50-day moving average||USD$20.1815|
|200-day moving average||USD$16.4682|
|Wall St. target price||USD$21.44|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$0.082|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing NextGen Healthcare stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of NextGen Healthcare's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
NextGen Healthcare's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 230x. In other words, NextGen Healthcare shares trade at around 230x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
NextGen Healthcare's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 3.2465. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into NextGen Healthcare's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
NextGen Healthcare's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$31.5 million.
The EBITDA is a measure of a NextGen Healthcare's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$549 million|
|Operating margin TTM||3.45%|
|Gross profit TTM||USD$308.3 million|
|Return on assets TTM||1.85%|
|Return on equity TTM||1.42%|
|Market capitalisation||USD$1.3 billion|
TTM: trailing 12 months
There are currently 1.2 million NextGen Healthcare shares held short by investors – that's known as NextGen Healthcare's "short interest". This figure is 0.3% down from 1.3 million last month.
There are a few different ways that this level of interest in shorting NextGen Healthcare shares can be evaluated.
NextGen Healthcare's "short interest ratio" (SIR) is the quantity of NextGen Healthcare shares currently shorted divided by the average quantity of NextGen Healthcare shares traded daily (recently around 427291.78082192). NextGen Healthcare's SIR currently stands at 2.92. In other words for every 100,000 NextGen Healthcare shares traded daily on the market, roughly 2920 shares are currently held short.
However NextGen Healthcare's short interest can also be evaluated against the total number of NextGen Healthcare shares, or, against the total number of tradable NextGen Healthcare shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case NextGen Healthcare's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 NextGen Healthcare shares in existence, roughly 20 shares are currently held short) or 0.0324% of the tradable shares (for every 100,000 tradable NextGen Healthcare shares, roughly 32 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against NextGen Healthcare.
Find out more about how you can short NextGen Healthcare stock.
We're not expecting NextGen Healthcare to pay a dividend over the next 12 months.
NextGen Healthcare's shares were split on a 2:1 basis on 27 October 2011. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your NextGen Healthcare shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for NextGen Healthcare shares which in turn could have impacted NextGen Healthcare's share price.
Over the last 12 months, NextGen Healthcare's shares have ranged in value from as little as $5.1 up to $23.8. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while NextGen Healthcare's is 1.1681. This would suggest that NextGen Healthcare's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
NextGen Healthcare, Inc. provides ambulatory-focused healthcare software and services solutions in the United States. The company offers NextGen Enterprise electronic health record (EHR), which stores and maintains clinical patient information; and a workflow module, prescription management, automatic document and letter generation, patient education, referral tracking, interfaces to billing and lab systems, physician alerts and reminders, and reporting and data analysis tools. Its products also comprise NextGen Enterprise PM, a practice management (PM) solution; NextGen Office, a cloud-based EHR and PM solution; NextGen Mobile; and NextGen Electronic Healthcare Transactions. In addition, it provides population health solutions, such as NextGen Population Health Analytics, NextGen Population Health Patient Care Management, and NextGen Population Health Performance Management; and patient engagement solutions comprising NextGen Patient Portal, NextGen Self Scheduling, NextGen Patient Pay, and NextGen Virtual Visits solutions. Further, the company offers NextGen Connect Integration Engine, NextGen Health Data Hub, and NextGen Share interoperability solutions; managed services, including NextGen Managed Cloud and NextGen Revenue Cycle Management Services; professional services; and client service and support. It serves managed service organizations, independent physician associations, accountable care organizations, ambulatory care centers, and community health centers through a sales force and reseller channel. The company was formerly known as Quality Systems, Inc. and changed its name to NextGen Healthcare, Inc. in September 2018. NextGen Healthcare, Inc. was founded in 1974 and is headquartered in Irvine, California.
Everything we know about the Achilles Therapeutics plc IPO, plus information on how to buy in.
Everything we know about the SEMrush Holdings Inc IPO, plus information on how to buy in.
Everything we know about the ChargePoint IPO, plus information on how to buy in.
Everything we know about the Kaltura Inc IPO, plus information on how to buy in.
Everything we know about the Rocket Lab IPO, plus information on how to buy in.
Everything we know about the Soho House IPO, plus information on how to buy in.
Everything we know about the VIZIO IPO, plus information on how to buy in.
Everything we know about the IDW Media Holdings Inc IPO, plus information on how to buy in.
Everything we know about the Karooooo Ltd IPO, plus information on how to buy in.
Everything we know about the Connect Biopharma Holdings Limited IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.